Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
Sell
33
BIB Quote, Financials, Valuation and Earnings
Last price:
$41.77
Seasonality move
:
11.71%
Day range:
$40.81 - $41.75
52-week range:
$33.78 - $69.56
Dividend yield:
2.27%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
8.6K
Avg. volume:
11.6K
1-year change:
-25.27%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIB
ProShares Ultra Nasdaq Biotechnology
|
-- | -- | -- | -- | -- |
|
QLD
ProShares Ultra QQQ
|
-- | -- | -- | -- | -- |
|
SKYU
ProShares Ultra Nasdaq Cloud Computing
|
-- | -- | -- | -- | -- |
|
TQQQ
ProShares UltraPro QQQ
|
-- | -- | -- | -- | -- |
|
UCYB
ProShares Ultra Nasdaq Cybersecurity
|
-- | -- | -- | -- | -- |
|
URE
ProShares Ultra Real Estate
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIB
ProShares Ultra Nasdaq Biotechnology
|
$41.56 | -- | -- | -- | $0.13 | 2.27% | -- |
|
QLD
ProShares Ultra QQQ
|
$91.42 | -- | -- | -- | $0.03 | 0.27% | -- |
|
SKYU
ProShares Ultra Nasdaq Cloud Computing
|
$26.76 | -- | -- | -- | $0.01 | 0.3% | -- |
|
TQQQ
ProShares UltraPro QQQ
|
$57.40 | -- | -- | -- | $0.20 | 1.72% | -- |
|
UCYB
ProShares Ultra Nasdaq Cybersecurity
|
$51.64 | -- | -- | -- | $0.14 | 2.05% | -- |
|
URE
ProShares Ultra Real Estate
|
$63.53 | -- | -- | -- | $0.26 | 2.39% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIB
ProShares Ultra Nasdaq Biotechnology
|
-- | 1.798 | -- | -- |
|
QLD
ProShares Ultra QQQ
|
-- | 2.195 | -- | -- |
|
SKYU
ProShares Ultra Nasdaq Cloud Computing
|
-- | 3.730 | -- | -- |
|
TQQQ
ProShares UltraPro QQQ
|
-- | 3.353 | -- | -- |
|
UCYB
ProShares Ultra Nasdaq Cybersecurity
|
-- | 1.285 | -- | -- |
|
URE
ProShares Ultra Real Estate
|
-- | 1.751 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIB
ProShares Ultra Nasdaq Biotechnology
|
-- | -- | -- | -- | -- | -- |
|
QLD
ProShares Ultra QQQ
|
-- | -- | -- | -- | -- | -- |
|
SKYU
ProShares Ultra Nasdaq Cloud Computing
|
-- | -- | -- | -- | -- | -- |
|
TQQQ
ProShares UltraPro QQQ
|
-- | -- | -- | -- | -- | -- |
|
UCYB
ProShares Ultra Nasdaq Cybersecurity
|
-- | -- | -- | -- | -- | -- |
|
URE
ProShares Ultra Real Estate
|
-- | -- | -- | -- | -- | -- |
ProShares Ultra Nasdaq Biotechnology vs. Competitors
-
Which has Higher Returns BIB or QLD?
ProShares Ultra QQQ has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares Ultra QQQ's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIBProShares Ultra Nasdaq Biotechnology-- -- -- QLDProShares Ultra QQQ-- -- -- -
What do Analysts Say About BIB or QLD?
ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra QQQ has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares Ultra QQQ, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares Ultra QQQ.
Company Buy Ratings Hold Ratings Sell Ratings BIBProShares Ultra Nasdaq Biotechnology0 0 0 QLDProShares Ultra QQQ0 0 0 -
Is BIB or QLD More Risky?
ProShares Ultra Nasdaq Biotechnology has a beta of 1.365, which suggesting that the stock is 36.499% more volatile than S&P 500. In comparison ProShares Ultra QQQ has a beta of 2.349, suggesting its more volatile than the S&P 500 by 134.941%.
-
Which is a Better Dividend Stock BIB or QLD?
ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 2.27%. ProShares Ultra QQQ offers a yield of 0.27% to investors and pays a quarterly dividend of $0.03 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Ultra QQQ pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIB or QLD?
ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Ultra QQQ quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares Ultra QQQ's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Ultra QQQ's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares Ultra QQQ. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIBProShares Ultra Nasdaq Biotechnology-- -- -- -- QLDProShares Ultra QQQ-- -- -- --
-
Which has Higher Returns BIB or SKYU?
ProShares Ultra Nasdaq Cloud Computing has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares Ultra Nasdaq Cloud Computing's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIBProShares Ultra Nasdaq Biotechnology-- -- -- SKYUProShares Ultra Nasdaq Cloud Computing-- -- -- -
What do Analysts Say About BIB or SKYU?
ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra Nasdaq Cloud Computing has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares Ultra Nasdaq Cloud Computing, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares Ultra Nasdaq Cloud Computing.
Company Buy Ratings Hold Ratings Sell Ratings BIBProShares Ultra Nasdaq Biotechnology0 0 0 SKYUProShares Ultra Nasdaq Cloud Computing0 0 0 -
Is BIB or SKYU More Risky?
ProShares Ultra Nasdaq Biotechnology has a beta of 1.365, which suggesting that the stock is 36.499% more volatile than S&P 500. In comparison ProShares Ultra Nasdaq Cloud Computing has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BIB or SKYU?
ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 2.27%. ProShares Ultra Nasdaq Cloud Computing offers a yield of 0.3% to investors and pays a quarterly dividend of $0.01 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Ultra Nasdaq Cloud Computing pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIB or SKYU?
ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Ultra Nasdaq Cloud Computing quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares Ultra Nasdaq Cloud Computing's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Ultra Nasdaq Cloud Computing's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares Ultra Nasdaq Cloud Computing. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIBProShares Ultra Nasdaq Biotechnology-- -- -- -- SKYUProShares Ultra Nasdaq Cloud Computing-- -- -- --
-
Which has Higher Returns BIB or TQQQ?
ProShares UltraPro QQQ has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares UltraPro QQQ's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIBProShares Ultra Nasdaq Biotechnology-- -- -- TQQQProShares UltraPro QQQ-- -- -- -
What do Analysts Say About BIB or TQQQ?
ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares UltraPro QQQ has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares UltraPro QQQ, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares UltraPro QQQ.
Company Buy Ratings Hold Ratings Sell Ratings BIBProShares Ultra Nasdaq Biotechnology0 0 0 TQQQProShares UltraPro QQQ0 0 0 -
Is BIB or TQQQ More Risky?
ProShares Ultra Nasdaq Biotechnology has a beta of 1.365, which suggesting that the stock is 36.499% more volatile than S&P 500. In comparison ProShares UltraPro QQQ has a beta of 3.522, suggesting its more volatile than the S&P 500 by 252.185%.
-
Which is a Better Dividend Stock BIB or TQQQ?
ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 2.27%. ProShares UltraPro QQQ offers a yield of 1.72% to investors and pays a quarterly dividend of $0.20 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares UltraPro QQQ pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIB or TQQQ?
ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares UltraPro QQQ quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares UltraPro QQQ's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares UltraPro QQQ's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares UltraPro QQQ. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIBProShares Ultra Nasdaq Biotechnology-- -- -- -- TQQQProShares UltraPro QQQ-- -- -- --
-
Which has Higher Returns BIB or UCYB?
ProShares Ultra Nasdaq Cybersecurity has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares Ultra Nasdaq Cybersecurity's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIBProShares Ultra Nasdaq Biotechnology-- -- -- UCYBProShares Ultra Nasdaq Cybersecurity-- -- -- -
What do Analysts Say About BIB or UCYB?
ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra Nasdaq Cybersecurity has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares Ultra Nasdaq Cybersecurity, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares Ultra Nasdaq Cybersecurity.
Company Buy Ratings Hold Ratings Sell Ratings BIBProShares Ultra Nasdaq Biotechnology0 0 0 UCYBProShares Ultra Nasdaq Cybersecurity0 0 0 -
Is BIB or UCYB More Risky?
ProShares Ultra Nasdaq Biotechnology has a beta of 1.365, which suggesting that the stock is 36.499% more volatile than S&P 500. In comparison ProShares Ultra Nasdaq Cybersecurity has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BIB or UCYB?
ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 2.27%. ProShares Ultra Nasdaq Cybersecurity offers a yield of 2.05% to investors and pays a quarterly dividend of $0.14 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Ultra Nasdaq Cybersecurity pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIB or UCYB?
ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Ultra Nasdaq Cybersecurity quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares Ultra Nasdaq Cybersecurity's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Ultra Nasdaq Cybersecurity's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares Ultra Nasdaq Cybersecurity. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIBProShares Ultra Nasdaq Biotechnology-- -- -- -- UCYBProShares Ultra Nasdaq Cybersecurity-- -- -- --
-
Which has Higher Returns BIB or URE?
ProShares Ultra Real Estate has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares Ultra Real Estate's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIBProShares Ultra Nasdaq Biotechnology-- -- -- UREProShares Ultra Real Estate-- -- -- -
What do Analysts Say About BIB or URE?
ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra Real Estate has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares Ultra Real Estate, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares Ultra Real Estate.
Company Buy Ratings Hold Ratings Sell Ratings BIBProShares Ultra Nasdaq Biotechnology0 0 0 UREProShares Ultra Real Estate0 0 0 -
Is BIB or URE More Risky?
ProShares Ultra Nasdaq Biotechnology has a beta of 1.365, which suggesting that the stock is 36.499% more volatile than S&P 500. In comparison ProShares Ultra Real Estate has a beta of 1.986, suggesting its more volatile than the S&P 500 by 98.588%.
-
Which is a Better Dividend Stock BIB or URE?
ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 2.27%. ProShares Ultra Real Estate offers a yield of 2.39% to investors and pays a quarterly dividend of $0.26 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Ultra Real Estate pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIB or URE?
ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Ultra Real Estate quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares Ultra Real Estate's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Ultra Real Estate's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares Ultra Real Estate. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIBProShares Ultra Nasdaq Biotechnology-- -- -- -- UREProShares Ultra Real Estate-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
